Clinical trials: Cirrhosis Portal
Liver Cirrhosis, Esophageal and Gastric Varices
A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism
The purpose of this study was to compare the effects of partial splenic artery embolization combined with endoscopic treatment and endoscopic treatment alone on portal hypertension in cirrhosis with hyperplenism or splenomegaly…
- Conditions
- Liver Cirrhosis, Esophageal and Gastric Varices, Hypersplenism
- Trial name
- NCT05055713
- Testing
- Endoscopic therapy+ beta blockers, Endoscopic therapy+ PSE+beta blockers, Endoscopic therapy
- Where
- China
- Volunteers
- 368 people
- Sponsor
- Qilu Hospital of Shandong University
Liver Cirrhosis, Gastric Varix
Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices
The aim of this study is to explore whether using endoscopic ultrasound (EUS) to assess gastric varices (GV) and giving additional treatment according to the diameter and blood flow of residual after endoscopic cyanoacrylate…
- Conditions
- Liver Cirrhosis, Gastric Varix, Portal Hypertension
- Trial name
- NCT05515861
- Testing
- Endoscopic ultrasound
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Renmin Hospital of Wuhan University
Chronic Liver Disease and Cirrhosis
Impact of Home-Based Aerobic and Resistance Training in Chronic Liver Disease: a Randomized Control Trial
The goal of this clinical trial is to evaluate whether home-based exercise interventions, including aerobic exercise (AE) and a combination of aerobic and resistance exercise (ARE), can improve physical and health-related…
- Trial name
- NCT06892366
- Testing
- Home-Based Aerobic Exercise Program, Home-Based Aerobic and Resistance Exercise (ARE) Group
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Hacettepe University
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Hepatic Encephalopathy
Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy
The purpose of this study is to compare a normal-protein diet containing branched-chain amino acids to a low-protein diet in patients with non-terminal cirrhosis (MELD < 25) who have developed an episode of hepatic encephalopathy…
- Trial name
- NCT00955500
- Testing
- Branched-chain amino acids, Maltodextrin
- Where
- 3 sites in Spain
- Volunteers
- 116 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatitis C, Liver Cirrhosis
Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3-4 million new infections and 350,000 deaths occurring each year…
- Trial name
- NCT03241823
- Testing
- Abdominal ultrasound ., Model for End-Stage Liver Disease, Fibro Scan.
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Portal Hypertension
Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
Portal hypertension is the result of an increased hepatic vascular resistance and portal inflow. The best established method to assess portal pressures is the determination of wedged hepatic venous pressure gradient (HVPG).
- Trial name
- DPH (NCT02975323)
- Testing
- Carvedilol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Aga Khan University
HCC, Liver Cirrhosis
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
In China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically…
- Conditions
- HCC, Liver Cirrhosis, Portal Hypertension
- Trial name
- NCT07350070
- Testing
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Tongji Hospital
Hepatic Encephalopathy, Cirrhosis
iPod Games in Hepatic Encephalopathy
To see if using ipod games can improve mental functioning
- Trial name
- NCT02154282
- Testing
- ipod games
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Cirrhosis, Liver, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients Undergoing TIPS Placement
ALTA is a multicenter consortium focused on the management of portal hypertension. ALTA TIPS is a longitudinal observational study of patients who are undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement.
- Trial name
- NCT03973372
- Where
- 14 sites in United States
- Volunteers
- 852 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute-On-Chronic Liver Failure, Cirrhosis and Chronic Liver Disease
Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features.
- Trial name
- PGE2 (NCT02965560)
- Testing
- plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Cirrhosis
Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients
Thrombosis occurring in the small intrahepatic, as well as in the large vessels is involved in the progression of cirrhosis. Anticoagulation could reduce morbidity and mortality in cirrhotic patients
- Trial name
- Childbenox (NCT02271295)
- Testing
- Enoxaparine
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis, Ascites
The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.
This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention.
- Conditions
- Cirrhosis, Ascites, Liver Diseases, Frailty
- Trial name
- NCT04675775
- Testing
- Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Michigan
Portosystemic Shunt, Pulmonary Hypertension
Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study
This study aims to establish a multi-center registry cohort of portosystemic shunt-associated pulmonary hypertension, with the goal of clarifying the epidemiology, clinical features, phenotypic classification, response to…
- Trial name
- NCT07481877
- Volunteers
- 300 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Hepatic Cirrhosis
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
Multicentric, observational and prospective study with two groups of treatment: Refractory ascites and non-refractory ascites. All patients should be prescribed beta-adrenergic blockers as primary or secondary profilaxis for…
- Trial name
- ALB-BET (NCT02163512)
- Where
- 2 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Portal Vein Thrombosis, Cirrhosis, Liver
Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
To prevent portal vein thrombosis (PVT) in patients with cirrhosis at risk for PVT by pharmacologic prophylaxis with intravenous antithrombin (AT-III).
- Trial name
- PiVoT (NCT04055389)
- Testing
- Antithrombin III
- Where
- United States
- Sponsor
- Jonathan Stine
Cirrhosis, Portal Hypertension
EUS-PPG vs HVPG in Portal Hypertension
The objective of this study is to evaluate the correlation of the calculated portal pressure gradient (PPG) obtained by direct portal and hepatic pressure measurements with a conventional 22 G needle guided by EUS and indirect…
- Trial name
- GRAPE (NCT05689268)
- Testing
- EUS-PPG and HVPG
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Hospital General Universitario de Alicante
Liver Diseases
Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a…
- Trial name
- 4D-MRI Liver (NCT05385237)
- Testing
- 4D-MRI
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Portal Hypertension, Liver Cirrhosis
Laparoscopic Versus Open Devascularization for Portal Hypertension, a Randomized Controlled Trial
Many patients with portal hypertension require surgical treatment each year,and Hassab's operation, or esophagogastric devascularization and splenectomy, is an elective procedure.
- Trial name
- NCT02178319
- Testing
- open surgical procedure, laparoscopic surgical procedure
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Liver Cirrhosis, Cirrhosis
Empagliflozin in Diuretic Refractory Ascites
Ascites is the most frequent complication of liver cirrhosis and results in increased morbidity and mortality but current medical management options are limited.
- Conditions
- Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic
- Trial name
- DRAin-Em 01 (NCT05013502)
- Testing
- Empagliflozin 10 MG
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Stanford University